BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (“HA”) technology, today reported strong revenue growth for the quarter ending March 31, 2008. Each of the company’s product lines experienced double-digit revenue increases during the quarter. Anika continued to strengthen its global position in joint health therapies with well-received initial response in Europe of ORTHOVISC®Mini, its new HA osteoarthritis treatment specifically targeted for smaller joints, and progress on a key U.S. clinical study of its single-injection osteoarthritis product, MONOVISC™, for the relief of knee pain.
